A new study shows that much of an older person with visual impairment's physical activity is achieved at home. Improved home lighting can help increase those at-home activity rates.

IDOC has partnered with 12 new vendors in the eye care industry and assisted Books & Benchmarks, expanding its rebate, discount, practice support, and other resource options for its members.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

Diffusion Optics Technology (DOT) spectacle lenses are intended to slow myopia progression in children via contrast management mechanism of action.

Myopia management in children is a crucial step to ensuring the overall health and wellness of our youth.

Phase 3 of the randomized, double-masked, placebo-controlled study had a primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome.

A new treatment option may be on the horizon for glaucoma patients.

Optometry Times chats with Michael Chaglasian, OD, FAAO during this year's Glaucoma 360 meeting in San Francisco, California.

Pairing the patient with the right therapy can yield dramatic results.

An investigative study of the Government Accountability Office was requested by a US House of Representatives committee to evaluate the consolidation and vertical integration of vision coverage.

The event, being held at the El Conquistador Resort in Puerto Rico, is offering programs for ophthalmologists and optometrists.

This article outlines which medications may be best to take to mitigate the onset of type 2 diabetes through weight loss, in addition to lessening sugar intake and other eating habits.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

Catch up on what happened in optometry during the week of February 5-February 9.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

Members of the University Professional and Technical Employees CWA Local 9119 drew picket lines on February 6 and 7 to protest unfair labor and bargaining practices upheld by University of California.

Cecelia Koetting, OD, FAAO, DIPABO chats with Optometry Times about her role with EnVision Summit's new optometry program and the excitement surrounding the event.